AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics


An Introduction

AI-powered drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions given the promise of lower costs and shorter development timelines. According to Grand View Research the global "AI in drug discovery" market should expand at a compound annual growth rate of 30% clip between now and 2030 which Morgan Stanley believes will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion! To that end, according to 2022 research by Boston Consulting Group, more than 150 small-molecule drugs were already in discovery and with more than 15 already in clinical trials.” Bottom line, a $50 billion AI drug discovery revolution is underway. 

The munKNEE AI-powered Drug Discovery Stocks Index

The following 8 clinical-stage companies use AI to facilitate the discovery and development of new drugs and are constituents in munKNEE's AI-powered Drug Discovery Stocks Index. They are ranked below in order of their stock performances last week and YTD along a description of each companies focus of operations and any recent news, commentary, and/or analysis:

  1. BioXcel Therapeutics (BTAI): up 66.4% last week; up 19.0% YTD
  2. Recursion Pharmaceuticals (RXRX); up 30.3% last week; up 33.4% YTD
    • has one of the world’s most extensive biological and chemical datasets and conducts millions of experiments per week using supercomputers, machine learning and automated robotic labs and has several compounds in phase 1 and 2 studies.
    •  recent news, commentary, and/or analysis:
  3. Absci Corporation (ABSI): up 24.0% last week; up 26.9% YTD
    • is focused on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
    •  recent news, commentary, and/or analysis: None
  4. Relay Therapeutics (RLAY): up 19.3% last week; down 1.5% YTD
    • is developing an AI-driven allosteric drug-discovery platform to detect interactions that occur on a protein of interest with an initial focus on precision oncology and genetic diseases.
    •  recent news, commentary, and/or analysis:
  5. Schrödinger (SDGR): up 17.8% last week; down 9.2% YTD
  6. AbCellera Biologics (ABCL): up 4.5% last week; down 6.5% YTD
  7. Exscientia (EXAI): up 2.2% last week; up 8.0% YTD
  8. Lantern Pharma (LTRN): down 2.1% last week; down 3.3% YTD


The munKNEE AI-powered Drug Discovery Stocks Index was up 18.0% last week and is now up 1.9% YTD.

More By This Author:

As Expected, Cannabis MSOs Continue To Decline
3 Poor Quarterly Financials Sink Cannabis LP Index
Get Ready: AI-Enabled Personal Computer Category About To Explode

Disclosure: None

This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.